ALSO NOTED: Merck KGaA names CEO;R&D facility planned;and much more...

> A $3.5 million tech incubator is planned for Flagstaff, AZ, the first step toward building a 200,000 square foot science and technology park to host expanding research operations. Backers hope that the initiative can help the state expand on its biotech business, though Arizona has traditionally lagged behind many other states in investing in the industry. Report

> Chutes & Ladders: Germany's Merck KGaA has named Karl-Ludwig Kley as its new CEO, succeeding Michael Roemer. Kley was given a significant amount of credit for the buyout of Switzerland's Serono recently. Report

> Gene Logic announced that its plan to transform itself into a pharma developer with a lineup of drug collaborations may proceed with a spinoff of its genomics business. Over the past year Gene Logic has downsized from 434 to 151 workers. Release

> Valeant Pharmaceuticals has filed an Investigational New Drug application with the FDA for Cesamet (nabilone) oral capsules for the treatment of cancer chemotherapy-induced neuropathic pain. Report

> Chutes & Ladders: Wyeth Pharmaceuticals, a division of Wyeth, has named Geno Germano, 46, president--U.S. and general manager, Wyeth Pharmaceuticals. Release

> Emergent BioSolutions has announced delivery of slightly less than one million doses of BioThrax to the Department of Health and Human Services. Release

> Clarient has been granted a new U.S. patent related to the detection and quantification of rare tumor cells in blood and bone marrow. Release

> Pfizer has won a preliminary injunction in Europe against a generic version of Lipitor. Report

And Finally… The FDA remains under considerable pressure to reform as lawmakers consider how the agency handles the fees it collects from drug developers. Article

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.